ITMI931631A0 - Composizioni farmaceutiche a rilascio controllato a base di uno o piu'sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. - Google Patents

Composizioni farmaceutiche a rilascio controllato a base di uno o piu'sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.

Info

Publication number
ITMI931631A0
ITMI931631A0 IT93MI1631A ITMI931631A ITMI931631A0 IT MI931631 A0 ITMI931631 A0 IT MI931631A0 IT 93MI1631 A IT93MI1631 A IT 93MI1631A IT MI931631 A ITMI931631 A IT MI931631A IT MI931631 A0 ITMI931631 A0 IT MI931631A0
Authority
IT
Italy
Prior art keywords
gamma
hydroxy
pharmaceutically acceptable
pharmaceutical compositions
acceptable salts
Prior art date
Application number
IT93MI1631A
Other languages
English (en)
Inventor
Ubaldo Conte
Manna Aldo La
Giuseppe Tessitore
Original Assignee
Ubaldo Conte
Manna Aldo
Giuseppe Tessitore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubaldo Conte, Manna Aldo, Giuseppe Tessitore filed Critical Ubaldo Conte
Publication of ITMI931631A0 publication Critical patent/ITMI931631A0/it
Priority to IT93MI001631A priority Critical patent/IT1266565B1/it
Priority to HU9402077A priority patent/HUT75150A/hu
Priority to AT94111279T priority patent/ATE189384T1/de
Priority to DE69422861T priority patent/DE69422861T2/de
Priority to EP94111279A priority patent/EP0635265B1/en
Priority to US08/278,517 priority patent/US5594030A/en
Priority to PL94304389A priority patent/PL176211B1/pl
Priority to RU94026104A priority patent/RU2140266C1/ru
Priority to JP6191998A priority patent/JP2930875B2/ja
Publication of ITMI931631A1 publication Critical patent/ITMI931631A1/it
Application granted granted Critical
Publication of IT1266565B1 publication Critical patent/IT1266565B1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT93MI001631A 1993-07-22 1993-07-22 Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. IT1266565B1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT93MI001631A IT1266565B1 (it) 1993-07-22 1993-07-22 Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
HU9402077A HUT75150A (en) 1993-07-22 1994-07-12 Controlled release pharmaceutical compositions based on salts of gamma hydroxy-butyric acid
EP94111279A EP0635265B1 (en) 1993-07-22 1994-07-20 Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid
DE69422861T DE69422861T2 (de) 1993-07-22 1994-07-20 Pharmazeutische Zusammensetzung mit kontrollierter Freigabe auf Grund von einer oder mehrerer pharmazeutischer verträglicher Salze von Gamma-Hydroxybuttersäure
AT94111279T ATE189384T1 (de) 1993-07-22 1994-07-20 Pharmazeutische zusammensetzung mit kontrollierter freigabe auf grund von einer oder mehrerer pharmazeutischer verträglicher salze von gamma-hydroxybuttersäure
US08/278,517 US5594030A (en) 1993-07-22 1994-07-21 Controlled release pharmaceutical compositions based on one or more pharmaceutically acceptable salts of gamma hydroxy-butyric acid
PL94304389A PL176211B1 (pl) 1993-07-22 1994-07-21 Środek farmaceutyczny w postaci powlekanego granulatu lub powlekanej tabletki do kontrolowanego uwalniania substancji czynnej i sposób wytwarzania środka farmaceutycznego w postaci powlekanego granulatu lub powlekanej tabletki do kontrolowanego uwalniania substancji czynnej
RU94026104A RU2140266C1 (ru) 1993-07-22 1994-07-21 Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения
JP6191998A JP2930875B2 (ja) 1993-07-22 1994-07-22 γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI001631A IT1266565B1 (it) 1993-07-22 1993-07-22 Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.

Publications (3)

Publication Number Publication Date
ITMI931631A0 true ITMI931631A0 (it) 1993-07-22
ITMI931631A1 ITMI931631A1 (it) 1995-01-22
IT1266565B1 IT1266565B1 (it) 1997-01-09

Family

ID=11366665

Family Applications (1)

Application Number Title Priority Date Filing Date
IT93MI001631A IT1266565B1 (it) 1993-07-22 1993-07-22 Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.

Country Status (9)

Country Link
US (1) US5594030A (it)
EP (1) EP0635265B1 (it)
JP (1) JP2930875B2 (it)
AT (1) ATE189384T1 (it)
DE (1) DE69422861T2 (it)
HU (1) HUT75150A (it)
IT (1) IT1266565B1 (it)
PL (1) PL176211B1 (it)
RU (1) RU2140266C1 (it)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
EP1072257A1 (en) 1998-04-17 2001-01-31 Taisho Pharmaceutical Co., Ltd Multiple-unit sustained release tablets
JP4367722B2 (ja) * 1998-04-17 2009-11-18 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤
US6211194B1 (en) 1998-04-30 2001-04-03 Duke University Solution containing nicotine
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
EP1316309A1 (en) * 1998-12-23 2003-06-04 Orphan Medical Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
MXPA03010006A (es) * 2001-05-01 2005-03-07 Regent Court Technologies Llc Producto de tabaco sin humo.
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
RU2210360C1 (ru) * 2002-09-19 2003-08-20 Общество С Ограниченной Ответственностью "Консорциум-Пик" Психотропное средство
WO2004041207A2 (en) * 2002-11-01 2004-05-21 Baylor Research Institute Ghb treatment methods
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN104397869B (zh) * 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
ES2436850T3 (es) 2009-08-31 2014-01-07 Zeria Pharmaceutical Co., Ltd. Comprimido para administración oral para lavado intestinal
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
FR2971422B1 (fr) 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
BR112013023380B1 (pt) * 2011-04-06 2021-03-23 Dow Global Technologies Llc Processo para produzir um derivado de celulose particulado
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 4-纈胺醯氧基丁酸的合成方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
AU2021293941B2 (en) * 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程(武汉)有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3159208A1 (en) * 2021-02-09 2022-08-09 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Beta-hydroxybutyrate salt granule and methods for producing the same
WO2022170677A1 (en) * 2021-02-09 2022-08-18 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Beta-hydroxybutyrate salt granule and methods for producing it
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド 1晩1回の低ナトリウムオキシベート組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE139519C (it) *
SU552084A1 (ru) * 1972-01-13 1977-03-30 Институт фармакологии АМН СССР Средство "оксибутират лити " дл лечени маниакально-депрессивного психоза и приступообразно протекающей шизофрении
DD139519A1 (de) * 1978-11-10 1980-01-09 Annedore Wehl Verfahren zur herstellung analgetischer formulierungen mit verbesserten gebrauchswerteigenschaften
EP0325086A3 (en) * 1987-11-23 1990-10-31 Jago Research Ag Novel methods for obtaining therapeutic systems with controlled release of the drug
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.

Also Published As

Publication number Publication date
JP2930875B2 (ja) 1999-08-09
DE69422861T2 (de) 2000-07-27
RU94026104A (ru) 1996-11-10
JPH0753365A (ja) 1995-02-28
ITMI931631A1 (it) 1995-01-22
HU9402077D0 (en) 1994-09-28
DE69422861D1 (de) 2000-03-09
US5594030A (en) 1997-01-14
HUT75150A (en) 1997-04-28
EP0635265B1 (en) 2000-02-02
PL176211B1 (pl) 1999-05-31
RU2140266C1 (ru) 1999-10-27
IT1266565B1 (it) 1997-01-09
ATE189384T1 (de) 2000-02-15
EP0635265A1 (en) 1995-01-25
PL304389A1 (en) 1995-01-23

Similar Documents

Publication Publication Date Title
ITMI931631A0 (it) Composizioni farmaceutiche a rilascio controllato a base di uno o piu'sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
ITBO910114A1 (it) Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
DK0510404T3 (da) Gastroresistente farmaceutiske formuleringer til oral administration indeholdende galdesyresalte
ITMI931324A1 (it) Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
FI961739L (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
OA09415A (fr) "Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique".
NO304988B1 (no) 11-benzaldoksim-17<beta>-metoksy-17<alfa>-metoksymetyl-°stradienderivater samt farmas°ytisk preparat inneholdende slike
FI922095L (fi) Substituerade karboxylsyraderivat
ITRM930147A0 (it) Procedimento per la preparazione di sali dell'acido clavulanico. (caso 970-9808)
ITTO920303A0 (it) "composizione farmaceutica antiinfiammatoria"
FI945510A7 (fi) Klavulaanihapon diamiinisuolat
DK0571243T3 (da) Thiochromanderivater, fremgangsmåder til fremstilling heraf samt farmaceutiske midler indeholdende d isse
ITMI942319A0 (it) Nuovi derivati dell'acido kojico
IT1282943B1 (it) Composizione farmaceutica iniettabile__a base di acido ursodesossicoli co o tauroursodesossicolico
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
FI943875L (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
FR2624736B1 (fr) Nouvelles compositions pharmaceutiques dispersibles dans l'eau a base d'ornidazole
NZ230854A (en) 1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions
FI940133A0 (fi) Uudet nikotiinihappojohdannaiset
IT1201478B (it) Composizioni farmaceutiche idrosolubili a base di sali dell'acido (-)cis-1,2-epossipropilfosfonico con amminoacidi
ITMI921191A0 (it) Composizione farmaceutica atta a migliorare la biodisponibilita' dell'acido eicosapentaenoico e decosaesaenoico
IT8421608A0 (it) Estere dell'acido salicilico avente attivita' mucosecretolitica, antinfiammatoria, analgesica, antipiretica adatto a dare sali farmaceuticamente accettabili; procedimento per la preparazione, e composizioni farmaceutiche contenenti l'estere o i suoi sali.
IT8819185A0 (it) Formulazione farmaceutica a base di acido meclofenamico per somministrazione rettale.
IT8822047A0 (it) Acido 8 amino 1 idrossiottan 1,1difosfonico, suoi sali o derivati e relative composizioni farmaceutiche
ITFI910264A0 (it) Procedimento per la produzione di un bollino farmaceutico od equivalente, e bollino cosi' realizzato

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970730